Recent methods for measuring dopamine D3 receptor occupancy in vivo: Importance for drug development

Frontiers in Pharmacology

Volumn 5 JUL, Issue , 2014, Pages

  Le Foll, Bernard ^a,b,c   Wilson, Alan A ^a,c   Graff, Ariel ^a,c   Boileau, Isabelle ^a,b,c   Di Ciano, Patricia ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

D2; D3; Dopamine; Occupancy; PET imaging

Indexed keywords

3 METHYLSPIPERONE C 11; 4 PROPYL 9 HYDROXYNAPHTHOXAZINE C 11; 4 PROPYL 9 HYDROXYNAPHTHOXAZINE H 3; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NAXAGOLIDE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

CATALEPSY; COGNITION; DRUG DEPENDENCE; DRUG DEVELOPMENT; HUMAN; IN VIVO STUDY; LOCOMOTION; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW; SENSITIVITY ANALYSIS;

EID: 84904750865     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00161     Document Type: Review

References (118)

1. Achat-Mendes, C., Grundt, P., Cao, J., Platt, D. M., Newman, A. H., and Spealman, R. D. (2010). Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J. Pharmacol. Exp. Ther. 334, 556-565. doi: 10.1124/jpet.110.167619
2. Andreoli, M., Tessari, M., Pilla, M., Valerio, E., Hagan, J. J., and Heidbreder, C. A. (2003). Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28, 1272-1280. doi: 10.1038/sj.npp.1300183
3. American Psychiatric Association. (2013). DSM-5. Washington, DC: American Psychiatric Publishing, 806.
4. Ball, K. T., Combs, T. A., and Beyer, D. N. (2011). Opposing roles for dopamine D1- and D2-like receptors in discrete cue-induced reinstatement of food seeking. Behav. Brain Res. 222, 390-393. doi: 10.1016/j.bbr.2011.03.064
5. Bergman, J., Roof, R. A., Furman, C. A., Conroy, J. L., Mello, N. K., Sibley, D. R.,et al. (2013). Modification of cocaine self-administration by buspirone (buspar(R)): potential involvement of D3 and D4 dopamine receptors. Int. J. Neuropsychopharmacol. 16, 445-458. doi: 10.1017/S1461145712000661
6. Boileau, I., Guttman, M., Rusjan, P., Adams, J. R., Houle, S., Tong, J.,et al. (2009). Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 132, 1366-1375. doi: 10.1093/brain/awn337
7. Boileau, I., Payer, D., Chugani, B., Lobo, D., Behzadi, A., Rusjan, P. M.,et al. (2013a). The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [(11)C]-(+)-propyl-hexahydro-naphtho-oxazin and [(11) C]raclopride. Addiction 108, 953-963. doi: 10.1111/add.12066
8. Boileau, I., Payer, D., Chugani, B., Lobo, D., Houle, S., Wilson, A. A.,et al. (2013b). In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [11C]-(+)-PHNO. Mol. Psychiatry doi: 10.1038/mp.2013.163 [Epub ahead of print].
9. Boileau, I., Payer, D., Houle, S., Behzadi, A., Rusjan, P. M., Tong, J.,et al. (2012). Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J. Neurosci. 32, 1353-1359. doi: 10.1523/JNEUROSCI.4371-11.2012
10. Bouthenet, M. L., Souil, E., Martres, M. P., Sokoloff, P., Giros, B., and Schwartz, J. C. (1991). Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 564, 203-219. doi: 10.1016/0006-8993(91)91456-B
11. Brennan, K. A., Carati, C., Lea, R. A., Fitzmaurice, P. S., and Schenk, S. (2009). Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats. Behav. Pharmacol. 20, 688-694. doi: 10.1097/FBP.0b013e328333a28d
12. Brody, A. L., London, E. D., Olmstead, R. E., Allen-Martinez, Z., Shulenberger, S., Costello, M. R., et al. (2010). Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence. Psychiatry Res. 183, 218-224. doi: 10.1016/j.pscychresns.2009.06.004
13. Caine, S. B., and Koob, G. F. (1994). Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J. Pharmacol. Exp. Ther. 270, 209-218.
14. Cervo, L., Cocco, A., Petrella, C., and Heidbreder, C. A. (2007). Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int. J. Neuropsychopharmacol. 10, 167-181. doi: 10.1017/S1461145705006449
15. Coenen, H. H., Laufer, P., Stocklin, G., Wienhard, K., Pawlik, G., Böcher-Schwarz, H. G.,et al. (1987). 3-N-(2-[18F]-fluoroethyl)-spiperone: a novel ligand for cerebral dopamine receptor studies with pet. Life Sci. 40, 81-88. doi: 10.1016/0024-3205(87)90255-4
16. Corrigall, W. A., and Coen, K. M. (1989). Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl.) 99, 473-478. doi: 10.1007/BF00589894
17. Corrigall, W. A., and Coen, K. M. (1991). Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl.) 104, 171-176. doi: 10.1007/BF02244174
18. Day, M., Bain, E., Marek, G., Saltarelli, M., and Fox, G. B. (2010). D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET. Int. J. Neuropsychopharmacol. 13, 291-292. doi: 10.1017/S1461145710000180
19. Diaz, J., Pilon, C., Le Foll, B., Gros, C., Triller, A., Schwartz, J. C.,et al. (2000). Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 20, 8677-8684.
20. Di Ciano, P., Underwood, R. J., Hagan, J. J., and Everitt, B. J. (2003). Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 28, 329-338. doi: 10.1038/sj.npp.1300148
21. Dodds, C. M., O'Neill, B., Beaver, J., Makwana, A., Bani, M., Merlo-Pich, E.,et al. (2012). Effect of the dopamine D(3) receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters. Appetite 59, 27-33. doi: 10.1016/j.appet.2012.03.007
22. Ehrin, E., Farde, L., de Paulis, T., Eriksson, L., Greitz, T., Johnström, P.,et al. (1985). Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. Int. J. Appl. Radiat. Isot. 36, 269-273. doi: 10.1016/0020-708X(85)90083-3
23. Frankle, W. G., and Laruelle, M. (2002). Neuroreceptor imaging in psychiatric disorders. Ann. Nucl. Med. 16, 437-446. doi: 10.1007/BF02988639
24. Gal, K., and Gyertyan, I. (2003). Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res. Bull. 61, 595-601. doi: 10.1016/S0361-9230(03)00217-X
25. Gal, K., and Gyertyan, I. (2006). Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend. 81, 63-70. doi: 10.1016/j.drugalcdep.2005.05.011
26. Gilbert, J. G., Newman, A. H., Gardner, E. L., Ashby, C. R. Jr.,Heidbreder, C. A., Pak, A. C.,et al. (2005). Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D(3) receptors. Synapse 57, 17-28. doi: 10.1002/syn.20152
27. Ginovart, N., Galineau, L., Willeit, M., Mizrahi, R., Bloomfield, P. M., Seeman, P.,et al. (2006). Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J. Neurochem. 97, 1089-1103. doi: 10.1111/j.1471-4159.2006.03840.x
28. Ginovart, N., Willeit, M., Rusjan, P., Graff, A., Bloomfield, P. M., Houle, S.,et al. (2007). Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J. Cereb. Blood Flow Metab. 27, 857-871.
29. Graff-Guerrero, A., Redden, L., Abi-Saab, W., Katz, D. A., Houle, S., Barsoum, P.,et al. (2010). Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int. J. Neuropsychopharmacol. 13, 273-287. doi: 10.1017/S1461145709990642
30. Graff-Guerrero, A., Willeit, M., Ginovart, N., Mamo, D., Mizrahi, R., Rusjan, P.,et al. (2008). Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum. Brain Mapp. 29, 400-410. doi: 10.1002/hbm.20392
31. Graham, W. C., Clarke, C. E., Boyce, S., Sambrook, M. A., Crossman, A. R., and Woodruff, G. N. (1990). Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res. 514, 103-110. doi: 10.1016/0006-8993(90)90440-M
32. Gross, G., and Drescher, K. (2012). The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb. Exp. Pharmacol. 213, 167-210. doi: 10.1007/978-3-642-25758-2_7
33. Grundt, P., Prevatt, K. M., Cao, J., Taylor, M., Floresca, C. Z., Choi, J. K.,et al. (2007). Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J. Med. Chem. 50, 4135-4146. doi: 10.1021/jm0704200
34. Gurevich, E. V., Bordelon, Y., Shapiro, R. M., Arnold, S. E., Gur, R. E., and Joyce, J. N. (1997). Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry 54, 225-232. doi: 10.1001/archpsyc.1997.01830150047009
35. Halldin, C., Farde, L., Hogberg, T., Mohell, N., Hall, H., Suhara, T.,et al. (1995). Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J. Nucl. Med. 36, 1275-1281.
36. Heidbreder, C. (2005). Novel pharmacotherapeutic targets for the management of drug addiction. Eur. J. Pharmacol. 526, 101-112. doi: 10.1016/j.ejphar.2005.09.038
37. Heidbreder, C. A., Andreoli, M., Marcon, C., Hutcheson, D. M.,Gardner, E. L., and Ashby C. R. Jr. (2007). Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict. Biol. 12, 35-50. doi: 10.1111/j.1369-1600.2007.00051.x
38. Heidbreder, C. A., Gardner, E. L., Xi, Z. X., Thanos, P. K., Mugnaini, M., Hagan, J. J.,et al. (2005). The role of central dopamine D(3) receptors in drug addiction: a review of pharmacological evidence. Brain Res. Brain Res. Rev. 49, 77-105. doi: 10.1016/j.brainresrev.2004.12.033
39. Higley, A. E., Kiefer, S. W., Li, X., Gaal, J., Xi, Z. X., and Gardner, E. L. (2012). Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats. Eur. J. Pharmacol. 659, 187-192. doi: 10.1016/j.ejphar.2011.02.046
40. Higley, A. E., Spiller, K., Grundt, P., Newman, A. H., Kiefer, S. W., Xi, Z. X.,et al. (2011). PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J. Psychopharmacol. 25, 263-273. doi: 10.1177/0269881109358201
41. Joyce, J. N. (2001). Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90, 231-259. doi: 10.1016/S0163-7258(01)00139-5
42. Joyce, J. N., Lexow, N., Bird, E., and Winokur, A. (1988). Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 2, 546-557. doi: 10.1002/syn.890020511
43. Joyce, J. N., and Millan, M. J. (2005). Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today 10, 917-925. doi: 10.1016/S1359-6446(05)03491-4
44. Joyce, J. N., Marshall, J. F., Bankiewicz, K. S., Kopin, I. J., and Jacobowitz, D. M. (1986). Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res. 382, 360-384. doi: 10.1016/0006-8993(86)91345-4
45. Khaled, M. A., Farid Araki, K., Li, B., Coen, K. M., Marinelli, P. W.,Varga, J.,et al. (2010). The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int. J. Neuropsychopharmacol. 13, 181-190. doi: 10.1017/S1461145709991064
46. Kiss, B., Horti, F., and Bobok, A. (2011). In vitro and in vivo comparison of [(3)H](+)-PHNO and [(3)H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D(3) from D(2) receptor sites. Synapse 65, 467-478. doi: 10.1002/syn.20867
47. LaHoste, G. J., and Marshall, J. F. (1991). Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: autoradiographic evidence against the dual mechanism hypothesis. Neuroscience 41, 473-481. doi: 10.1016/0306-4522(91)90342-L
48. Le Foll, B., and Boileau, I. (2013). Repurposing buspirone for drug addiction treatment. Int. J. Neuropsychopharmacol. 16, 251-253. doi: 10.1017/S1461145712000995
49. Le Foll, B., Diaz, J., and Sokoloff, P. (2003). Increased dopamine D3 receptor expression accompanying behavioural sensitization to nicotine in rats. Synapse 47, 176-183. doi: 10.1002/syn.10170
50. Le Foll, B., Diaz, J., and Sokoloff, P. (2005a). Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci. 76, 1281-1296. doi: 10.1016/j.lfs.2004.09.018
51. Le Foll, B., Diaz, J., and Sokoloff, P. (2005b). A single cocaine exposure increases BDNF and D3 receptor expressions: implications for drug-conditioning. Neuroreport 16, 175-178. doi: 10.1097/00001756-200502080-00022
52. Le Foll, B., Goldberg, S. R., and Sokoloff, P. (2005c). The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49, 525-541. doi: 10.1016/j.neuropharm.2005.04.022
53. Le Foll, B., Sokoloff, P., Stark, H., and Goldberg, S. R. (2005d). Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 30, 720-730. doi: 10.1038/sj.npp.1300622
54. Le Foll, B., Frances, H., Diaz, J., Schwartz, J. C., and Sokoloff, P. (2002). Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 15, 2016-2026. doi: 10.1046/j.1460-9568.2002.02049.x
55. Le Foll, B., Gallo, A., Le Strat, Y., Lu, L., and Gorwood, P. (2009). Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav. Pharmacol. 20, 1-17. doi: 10.1097/FBP.0b013e3283242f05
56. Le Foll, B., and Goldberg, S. R. (2005). Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol. Sci. 26, 287-293. doi: 10.1016/j.tips.2005.04.005
57. Le Foll, B., Goldberg, S. R., and Sokoloff, P. (2007). Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin. Investig. Drugs 16, 45-57. doi: 10.1517/13543784.16.1.45
58. Le Foll, B., Guranda, M., Wilson, A. A., Houle, S., Rusjan, P. M., Wing, V. C.,et al. (2014). Elevation of dopamine induced by cigarette smoking: novel insights from a [C]-(+)-PHNO PET study in humans. Neuropsychopharmacology 39, 415-424. doi: 10.1038/npp.2013.209
59. Le Foll, B., Schwartz, J. C., and Sokoloff, P. (2000). Dopamine D3 receptor agents as potential new medications for drug addiction. Eur. Psychiatry 15, 140-146. doi: 10.1016/S0924-9338(00)00219-4
60. Leggio, G. M., Camillieri, G., Platania, C. B., Castorina, A., Marrazzo, G., Torrisi, S. A.,et al. (2014). Dopamine D3 receptor is necessary for ethanol consumption: an approach with buspirone. Neuropsychopharmacology 39, 2017-2028. doi: 10.1038/npp.2014.51
61. Levesque, D., Martres, M. P., Diaz, J., Griffon, N., Lammers, C. H., Sokoloff, P.,et al. (1995). A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 92, 1719-1723. doi: 10.1073/pnas.92.5.1719
62. Liu, X., Jernigen, C., Gharib, M., Booth, S., Caggiula, A. R., and Sved, A. F. (2010). Effects of dopamine antagonists on drug cue-induced reinstatement of nicotine-seeking behavior in rats. Behav. Pharmacol. 21, 153-160. doi: 10.1097/FBP.0b013e328337be95
63. Martinez, D., Carpenter, K. M., Liu, F., Slifstein, M., Broft, A., Friedman, A. C.,et al. (2011). Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am. J. Psychiatry 168, 634-641. doi: 10.1176/appi.ajp.2010.10050748
64. Martinez, D., Gil, R., Slifstein, M., Hwang, D. R., Huang, Y., Perez, A.,et al. (2005). Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol. Psychiatry 58, 779-786. doi: 10.1016/j.biopsych.2005.04.044
65. Martinez, D., and Narendran, R. (2010). Imaging neurotransmitter release by drugs of abuse. Curr. Top. Behav. Neurosci. 3, 219-245. doi: 10.1007/7854_2009_34
66. Martinez, D., Narendran, R., Foltin, R. W., Slifstein, M., Hwang, D. R., Broft, A.,et al. (2007). Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am. J. Psychiatry 164, 622-629. doi: 10.1176/appi.ajp.164.4.622
67. Matuskey, D., Gallezot, J.-D., Lim, K., Zheng, M.-Q., Lin, S., and Carson, R. (2013). Subcortical D3/D2 receptor binding in cocaine dependent humans. J. Nuclear Med. 52(Suppl. 1):1284.
68. McCormick, P. N., Wilson, V. S., Wilson, A. A., and Remington, G. J. (2013). Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors. Pharmacol. Res. 70, 66-71. doi: 10.1016/j.phrs.2013.01.002
69. Millan, M. J., Dekeyne, A., Rivet, J. M., Dubuffet, T., Lavielle, G., and Brocco, M. (2000). S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293, 1063-1073.
70. Millan, M. J., Di Cara, B., Dekeyne, A., Panayi, F., De Groote, L., Sicard, D.,et al. (2007). Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J. Neurochem. 100, 1047-1061. doi: 10.1111/j.1471-4159.2006.04262.x
71. Millan, M. J., Loiseau, F., Dekeyne, A., Gobert, A., Flik, G., Cremers, T. I.,et al. (2008). S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J. Pharmacol. Exp. Ther. 324, 1212-1226. doi: 10.1124/jpet.107.134536
72. Morissette, M., Goulet, M., Grondin, R., Blanchet, P., Bedard, P. J., Di Paolo, T.,et al. (1998). Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10, 2565-2573. doi: 10.1046/j.1460-9568.1998.00264.x
73. Morris, E. D., Lucas, M. V., and Cosgrove, K. P. (2013). "How to study smoking and drinking with PET," in Positron Emission Tomography - Recent Developments in Instrumentation, Research and Clinical Oncological Practice, ed. S. Misciagna (Rijeka: Intech). doi: 10.5772/57414
74. Mugnaini, M., Iavarone, L., Cavallini, P., Griffante, C., Oliosi, B., Savoia, C.,et al. (2013). Occupancy of brain dopamine d(3) receptors and drug craving: a translational approach. Neuropsychopharmacology 38, 302-312. doi: 10.1038/npp.2012.171
75. Mukherjee, J., Yang, Z. Y., Lew, R., Brown, T., Kronmal, S., Cooper, M. D.,et al. (1997). Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. Synapse 27, 1-13. doi: 10.1002/(SICI)1098-2396(199709)27:1≤1::AID-SYN1≥3.0.CO;2-9
76. Nakajima, S., Gerretsen, P., Takeuchi, H., Caravaggio, F., Chow, T., Le Foll, B.,et al. (2013). The potential role of dopamine D3 receptor neurotransmission in cognition. Eur. Neuropsychopharmacol. 23, 799-813. doi: 10.1016/j.euroneuro.2013.05.006
77. Narendran, R., Slifstein, M., Guillin, O., Hwang, Y., Hwang, D. R., Scher, E.,et al. (2006). Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60, 485-495. doi: 10.1002/syn.20325
78. Nathan, P. J., O'Neill, B. V., Mogg, K., Bradley, B. P., Beaver, J., Bani, M.,et al. (2012). The effects of the dopamine D(3) receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int. J. Neuropsychopharmacol. 15, 149-161. doi: 10.1017/S1461145711001052
79. Newman, A. H., Grundt, P., and Nader, M. A. (2005). Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem. 48, 3663-3679. doi: 10.1021/jm040190e
80. Orio, L., Wee, S., Newman, A. H., Pulvirenti, L., and Koob, G. F. (2010). The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict. Biol. 15, 312-323. doi: 10.1111/j.1369-1600.2010.00211.x
81. Parsey, R. V., and Mann, J. J. (2003). Applications of positron emission tomography in psychiatry. Semin. Nucl. Med. 33, 129-135. doi: 10.1053/snuc.2003.127302
82. Payer, D. E., Behzadi, A., Kish, S. J., Houle, S., Wilson, A. A., Rusjan, P. M.,et al. (2014). Heightened D(3) dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [(11)C]-(+)-PHNO. Neuropsychopharmacology 39, 311-318. doi: 10.1038/npp.2013.192
83. Pickens, R., and Thompson, T. (1968). Cocaine-reinforced behavior in rats: effects of reinforcement magnitude and fixed-ratio size. J. Pharmacol. Exp. Ther. 161, 122-129.
84. Pritchard, L. M., Newman, A. H., McNamara, R. K., Logue, A. D., Taylor, B., Welge, J. A.,et al. (2007). The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol. Biochem. Behav. 86, 718-726. doi: 10.1016/j.pbb.2007.02.019
85. Rabiner, E. A., and Laruelle, M. (2010). Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET). Int. J. Neuropsychopharmacol. 13, 289-290. doi: 10.1017/S1461145710000088
86. Rabiner, E. A., Slifstein, M., Nobrega, J., Plisson, C., Huiban, M., Raymond, R.,et al. (2009). In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63, 782-793. doi: 10.1002/syn.20658
87. Reavill, C., Taylor, S. G., Wood, M. D., Ashmeade, T., Austin, N. E., Avenell, K. Y.,et al. (2000). Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 294, 1154-1165.
88. Robarge, M. J., Husbands, S. M., Kieltyka, A., Brodbeck, R., Thurkauf, A., and Newman, A. H. (2001). Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype. J. Med. Chem. 44, 3175-3186. doi: 10.1021/jm010146o
89. Robinson, S. W., and Caron, M. G. (1996). Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells. J. Neurochem. 67, 212-219. doi: 10.1046/j.1471-4159.1996.67010212.x
90. Ross, J. T., Corrigall, W. A., Heidbreder, C. A., and LeSage, M. G. (2007). Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur. J. Pharmacol. 559, 173-179. doi: 10.1016/j.ejphar.2007.01.004
91. Ryoo, H. L., Pierrotti, D., and Joyce, J. N. (1998). Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13, 788-97. doi: 10.1002/mds.870130506
92. Searle, G., Beaver, J. D., Comley, R. A., Bani, M., Tziortzi, A., Slifstein, M.,et al. (2010). Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol. Psychiatry 68, 392-399. doi: 10.1016/j.biopsych.2010.04.038
93. Sibley, D. R., and Monsma, F. J. (1992). Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13, 61-69. doi: 10.1016/0165-6147(92)90025-2
94. Sokoloff, P., Diaz, J., Le Foll, B., Guillin, O., Leriche, L., Bezard, E.,et al. (2006). The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 5, 25-43. doi: 10.2174/187152706784111551
95. Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L., and Schwartz, J. C. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146-151. doi: 10.1038/347146a0
96. Song, R., Yang, R. F., Wu, N., Su, R. B., Li, J., Peng, X. Q.,et al. (2012). YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict. Biol. 17, 259-273. doi: 10.1111/j.1369-1600.2011.00317.x
97. Staley, J. K., and Mash, D. C. (1996). Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci. 16, 6100-6106.
98. Suehiro, M., Dannals, R. F., Scheffel, U., Stathis, M., Wilson, A. A., Ravert, H. T.,et al. (1990). In vivo labeling of the dopamine D2 receptor with N-11C-methyl-benperidol. J. Nucl. Med. 31, 2015-2021.
99. Thanos, P. K., Katana, J. M., Ashby, C. R. Jr., Michaelides, M., Gardner, E. L., Heidbreder, C. A.,et al. (2005). The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol. Biochem. Behav. 81, 190-197. doi: 10.1016/j.pbb.2005.03.013
100. Tziortzi, A. C., Searle, G. E., Tzimopoulou, S., Salinas, C., Beaver, J. D., Jenkinson, M.,et al. (2011). Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54, 264-277. doi: 10.1016/j.neuroimage.2010.06.044
101. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Ding, Y. S., Sedler, M.,et al. (2001). Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am. J. Psychiatry 158, 2015-2021. doi: 10.1176/appi.ajp.158.12.2015
102. Volkow, N. D., Fowler, J. S., and Wang, G. J. (2003a). The addicted human brain: insights from imaging studies. J. Clin. Invest. 111, 1444-1451. doi: 10.1172/JCI18533
103. Volkow, N. D., Fowler, J. S., and Wang, G. J. (2003b). Positron emission tomography and single-photon emission computed tomography in substance abuse research. Semin. Nucl. Med. 33, 114-128. doi: 10.1053/snuc.2003.127300
104. Vorel, S. R., Ashby, C. R. Jr., Paul, M., Liu, X., Hayes, R., Hagan, J. J.,et al. (2002). Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 22, 9595-9603.
105. Wagner, H. N. Jr., Burns, H. D., Dannals, R. F., Wong, D. F., Langstrom, B., Duelfer, T.,et al. (1983). Imaging dopamine receptors in the human brain by positron tomography. Science 221, 1264-1266. doi: 10.1126/science.6604315
106. Watson, D. J., Loiseau, F., Ingallinesi, M., Millan, M. J., Marsden, C. A., and Fone, K. C. (2012a). Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 37, 770-786. doi: 10.1038/npp.2011.254
107. Watson, D. J., Marsden, C. A., Millan, M. J., and Fone, K. C. (2012b). Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int. J. Neuropsychopharmacol. 15, 471-484. doi: 10.1017/S1461145711000435
108. Weber, B., Schlicker, E., Sokoloff, P., and Stark, H. (2001). Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists. Br. J. Pharmacol. 133, 1243-1248. doi: 10.1038/sj.bjp.0704192
109. Willeit, M., Ginovart, N., Kapur, S., Houle, S., Hussey, D., Seeman, P.,et al. (2006). High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol. Psychiatry 59, 389-3894. doi: 10.1016/j.biopsych.2005.09.017
110. Wilson, A. A., McCormick, P., Kapur, S., Willeit, M., Garcia, A., Hussey, D.,et al. (2005). Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 48, 4153-4160. doi: 10.1021/jm050155n
111. Wise, R. A., Spindler, J., deWit, H., and Gerberg, G. J. (1978). Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food. Science 201, 262-264. doi: 10.1126/science.566469
112. Woolverton, W. L. (1986). Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol. Biochem. Behav. 24, 531-535. doi: 10.1016/0091-3057(86)90553-8
113. Xi, Z. X., Gilbert, J., Campos, A. C., Kline, N., Ashby, C. R. Jr., Hagan, J. J.,et al. (2004). Blockade of mesolimbic dopamine D(3) receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl.) 176, 57-65. doi: 10.1007/s00213-004-1858-y
114. Xi, Z. X., Gilbert, J. G., Pak, A. C., Ashby, C. R. Jr., Heidbreder, C. A., and Gardner, E. L. (2005). Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur. J. Neurosci. 21, 3427-3438. doi: 10.1111/j.1460-9568.2005.04159.x
115. Xi, Z. X., Newman, A. H., Gilbert, J. G., Pak, A. C., Peng, X. Q., Ashby, C. R. Jr.,et al. (2006). The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31, 1393-1405. doi: 10.1038/sj.npp.1300912
116. Xu, M., Koeltzow, T. E., Santiago, G. T., Moratalla, R., Cooper, D. C., Hu, X. T.,et al. (1997). Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 19, 837-848. doi: 10.1016/S0896-6273(00)80965-4
117. Yokel, R. A., and Wise, R. A. (1975). Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science 187, 547-549. doi: 10.1126/science.1114313
118. Yuan, J., Chen, X., Brodbeck, R., Primus, R., Braun, J., Wasley, J. W.,et al. (1998). NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. Bioorg. Med. Chem. Lett. 8, 2715-2718. doi: 10.1016/S0960-894X(98)00469-7